Squarepoint
AQST icon

Squarepoint’s Aquestive Therapeutics AQST Stock Holding History

Squarepoint’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-81,000
Closed -$345K – 4026
2024
Q1 		$345K Buy
+81,000
New +$270K ﹤0.01% 3298

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $52.3B AUM 19.7% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Squarepoint's AQST Position: Q3 2026 in Review

Squarepoint reduced its Aquestive Therapeutics (AQST) stake by 36% in Q3 2026, selling an estimated $112K and leaving 45,260 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #4040.

Squarepoint first reported a position in AQST in Q4 2018 and has held it in 19 quarters since. The position peaked at $1.04M in Q1 2026. 110 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

  • Squarepoint held 45,260 shares of Aquestive Therapeutics worth $210K as of Q3 2026.
  • Squarepoint sold 25,162 Aquestive Therapeutics shares in Q3 2026, an estimated $112K.
  • Aquestive Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #4040 holding.
  • Squarepoint first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 19 quarters since.
  • Squarepoint's Aquestive Therapeutics position peaked at $1.04M in Q1 2026.
  • 110 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.